Poland· PL-100499945
Truqap
A capivasertib product containing capivasertibum, registered in Poland by AstraZeneca AB. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Capivasertib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX27 (capivasertib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Capivasertib · ATC L01EX27
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of capivasertib costs, country by country.
Normalised to the WHO defined daily dose (0.46 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Capivasertib · price per daily dose (0.46 g)
USD · FX 28 Sept 2026
- CH Switzerland$320.95
The record
At a glance
URPL (Poland)- Active substance
- Capivasertibum
- Manufacturer
- AstraZeneca AB
- Country
- Poland (PL)
- ATC code
- L01EX27
- ATC class
- Capivasertib
- Defined daily dose
- 0.46 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05000456083119
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Capivasertib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTRUQAPAstraZeneca Pharmaceuticals LP
- SwitzerlandTruqap 160 mg, FilmtablettenAstraZeneca AG
- CzechiaTRUQAPAstraZeneca AB, Södertälje
- SpainTRUQAP 160 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- FinlandTRUQAPAstraZeneca AB
- BelgiumTruqap 160 mgAstraZeneca
- IcelandTruqapAstraZeneca AB*
- NetherlandsTRUQAP 160 mg filmomhulde tablettenAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Truqap
- Liechtenstein · Truqap
- Norway · Truqap
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cc9d1b6a-ef5b-4636-8f19-f1429a051a80 GET /v1/drugs/cc9d1b6a-ef5b-4636-8f19-f1429a051a80?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "160 mg",
"packaging": "05000456083119 ¦ Rpz ¦ EU/1/24/1820/001 ¦ 157075\n64 tabl.",
"substance": "Capivasertibum 160 mg",
"common_name": "Capivasertibum",
"pl_product_id": "100499945",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about capivasertib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.